[go: up one dir, main page]

LT2001045A - Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui - Google Patents

Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui

Info

Publication number
LT2001045A
LT2001045A LT2001045A LT2001045A LT2001045A LT 2001045 A LT2001045 A LT 2001045A LT 2001045 A LT2001045 A LT 2001045A LT 2001045 A LT2001045 A LT 2001045A LT 2001045 A LT2001045 A LT 2001045A
Authority
LT
Lithuania
Prior art keywords
therapeutic proteins
compositions
downmodulating
immune response
agents
Prior art date
Application number
LT2001045A
Other languages
English (en)
Other versions
LT4920B (lt
Inventor
Jiahua Qian
Leon W. Hoyer
Mary Collins
Gary S. Gray
Original Assignee
Genetics Institute,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute,Inc. filed Critical Genetics Institute,Inc.
Publication of LT2001045A publication Critical patent/LT2001045A/lt
Publication of LT4920B publication Critical patent/LT4920B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LT2001045A 1998-09-21 2001-04-20 Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui LT4920B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21

Publications (2)

Publication Number Publication Date
LT2001045A true LT2001045A (lt) 2002-01-25
LT4920B LT4920B (lt) 2002-06-25

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2001045A LT4920B (lt) 1998-09-21 2001-04-20 Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui

Country Status (21)

Country Link
EP (1) EP1115423A1 (lt)
JP (1) JP2002526455A (lt)
KR (1) KR20010085830A (lt)
CN (1) CN1331602A (lt)
AU (1) AU761206B2 (lt)
BR (1) BR9913991A (lt)
CA (1) CA2343916A1 (lt)
CZ (1) CZ20011021A3 (lt)
EA (1) EA005236B1 (lt)
HK (1) HK1039059A1 (lt)
HU (1) HUP0103960A3 (lt)
IL (1) IL142069A0 (lt)
LT (1) LT4920B (lt)
LV (1) LV12768B (lt)
MX (1) MXPA01002898A (lt)
NO (1) NO20011412L (lt)
NZ (1) NZ511034A (lt)
PL (1) PL346796A1 (lt)
SI (1) SI20626A (lt)
WO (1) WO2000016801A1 (lt)
ZA (1) ZA200103156B (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
JP2003534291A (ja) * 2000-05-19 2003-11-18 ザ センター フォー ブラッド リサーチ インク Ｐ−セレクチン活性の変調による止血障害の診断及び治療方法
WO2005010483A2 (en) * 2003-06-10 2005-02-03 Smiths Detection Inc. Sensor arrangement
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
CA2110518C (en) 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
CA2200869A1 (en) * 1994-10-19 1996-05-02 Bruce C. Trapnell Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
JP4751493B2 (ja) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
ATE356634T1 (de) * 1997-01-10 2007-04-15 Biogen Idec Inc Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
AU733062B2 (en) * 1997-06-20 2001-05-03 Biogen Idec Ma Inc. CD154 blockade therapy for therapeutic protein inhibitor syndrome
US8112896B2 (en) 2009-11-06 2012-02-14 Hexagon Metrology Ab Articulated arm

Also Published As

Publication number Publication date
AU6057899A (en) 2000-04-10
BR9913991A (pt) 2001-07-03
NO20011412D0 (no) 2001-03-20
CA2343916A1 (en) 2000-03-30
LT4920B (lt) 2002-06-25
HUP0103960A2 (hu) 2002-02-28
PL346796A1 (en) 2002-02-25
AU761206B2 (en) 2003-05-29
WO2000016801A9 (en) 2000-10-26
KR20010085830A (ko) 2001-09-07
CZ20011021A3 (cs) 2001-10-17
JP2002526455A (ja) 2002-08-20
HUP0103960A3 (en) 2003-09-29
EP1115423A1 (en) 2001-07-18
EA005236B1 (ru) 2004-12-30
NO20011412L (no) 2001-05-16
SI20626A (sl) 2002-02-28
IL142069A0 (en) 2002-03-10
LV12768A (en) 2001-12-20
MXPA01002898A (es) 2002-06-04
EA200100385A1 (ru) 2001-10-22
NZ511034A (en) 2004-03-26
WO2000016801A1 (en) 2000-03-30
LV12768B (lv) 2002-06-20
CN1331602A (zh) 2002-01-16
ZA200103156B (en) 2002-07-18
HK1039059A1 (zh) 2002-04-12

Similar Documents

Publication Publication Date Title
IL159422A0 (en) Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
WO1995021601A3 (en) Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
DE69727142D1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
WO2002060955A3 (en) Modified antibodies and methods of use
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
PL329940A1 (en) Compositions for once-a-day administration for use in treating diseases involving mediator effect of cyclooxygenase-2
WO1997040072A3 (en) Adam proteins and uses thereof
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
AU5774699A (en) Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
LT2001045A (lt) Kompozicijos ir jų panaudojimas imuninio atsako į terapinius baltymus supresiniam moduliavimui
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
TR200200278T2 (tr) Kalsilitik bileşimler
IL106237A0 (en) Piperidyl amides,sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
ZA943610B (en) Oligopeptides derived from c-reactive protein fragments
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO1999058098A8 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO

Legal Events

Date Code Title Description
PD9A Change of patent owner

Owner name: AMERICAN RED CROSS, US

Free format text: FORMEROWNER: GENETICS INSTITUTE, LLC, US

Effective date: 20031223

MM9A Lapsed patents

Effective date: 20050921